NHS Approves First Major Stomach Cancer Advance in a Decade

For the first time in nearly a decade, people facing aggressive stomach cancer have a powerful new weapon in their fight for survival.

The NHS has approved durvalumab, an immunotherapy drug that helps the body's immune system attack cancer cells. The treatment is now available for adults whose stomach cancer hasn't spread extensively and can be removed through surgery.

The approval affects around 1,500 people every year across the UK. Clinical trials showed the drug, combined with chemotherapy, extends the time before cancer returns and improves overall survival rates.

Helen Knight, director of medicines evaluation at the National Institute for Health and Care Excellence, called stomach cancer "a devastating disease with high rates of recurrence after surgery." She emphasized the urgent need for treatments that meaningfully extend both length and quality of life.

The breakthrough addresses one of the most heartbreaking aspects of stomach cancer treatment. Even after successful surgery, many patients face constant fear that their cancer will return. The recurrence rates have been stubbornly high for years.

Stomach cancer affects about 6,800 people in the UK annually, making it the 18th most common cancer in the country. Symptoms include difficulty swallowing, unexplained weight loss, persistent indigestion, and nausea.

The Ripple Effect

Beyond the immediate medical benefits, this approval represents hope for families who have watched loved ones endure life-altering surgery only to face recurring cancer. Sheena Dewan from Stomach Cancer UK called it "a real opportunity for lower recurrence and longer survival."

The treatment gives patients something precious: more time with family, more time at work, and more time to live well beyond treatment. For some, it offers the possibility of cure.

Durvalumab works by harnessing immunotherapy, a relatively newer approach that trains the body's natural defenses to recognize and fight cancer cells. This method represents a shift from traditional treatments that directly attack tumors but can also damage healthy tissue.

The drug is manufactured by AstraZeneca and marketed under the brand name Imfinzi. Its approval follows rigorous testing that demonstrated real benefits for patients facing one of the toughest cancer diagnoses.

After years of limited progress, stomach cancer patients finally have reason for renewed hope.